A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination

American Journal of Medicine

Volumn 109, Issue 3, 2000, Pages 241-244

  Saab, Sammy ^a   Martin, Paul ^a   Yee Jr , Hal F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ARTICLE; HEALTH CARE COST; HEALTH CARE PLANNING; HEPATITIS A; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SEROLOGY; VACCINATION;

ADULT; AGED; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS ANTIBODIES; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0034663281     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00469-1     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention website. Available at: www.cdc.gov. Accessed October 20, 1999.
2. Hadler S.C. Global impact of hepatitis A virus infection changing patterns . Hollinger F.B., Lemon S.M., Margolis H. Viral Hepatitis and Liver Disease. Proceedings of the 1990 International Symposium of Viral Hepatitis and Liver Disease Contemporary Issues and Future Prospects . 1991;14-20 Williams & Wilkins, Baltimore.
3. Werzerber A., Mensch B., Kuter B., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. NEJM. 327:1992;453-457.
4. Innis B.L., Snitbhan R., Kunasol P., et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 271:1994;1328-1334.
5. Niu M.T., Salive M., Krueger C., Ellenberg S.S. Two-year review of hepatitis A vaccine safety data from the adverse event reporting system (VAERS) . Clin Infect Dis. 26:1998;1475-1476.
6. Wiens B., Bohidar N., Pigeon J., et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol. 49:1996;235-241.
7. van Damme P., Thoelen S., Cramm M., et al. Inactivated hepatitis A vaccine reactogenicity, immunogenicity, and long-term antibody persistence . J Med Virol. 44:1994;446-451.
8. Prevention of hepatitis A through active or passive immunization recommendation of the Advisory Committee on Immunization Practices (ACIP) . MMWR. 48:1999;1-37.
9. Hepatitis A vaccination of men who have sex with men - Atlanta, Georgia 1996-1997. MMWR. 47:1998;308-401.
10. Katz M.H., Hsu L., Wong E., et al. Seroprevalence of and risk factors for hepatitis A infection among young homosexual and bisexual men. J Infect Dis. 175:1997;1225-1229.
11. Villano S.A., Nelson Ke, Vlahov D., et al. Hepatitis A among homosexual men and injection drug users more evidence for vaccination . Clin Infect Dis. 25:1997;726-728.
12. Corey L., Holmes K.K. Sexual transmission of hepatitis A in homosexual men. NEJM. 302:1980;435-438.
13. Kryger P., Pedersen N.S., Mathiesen L., Nielsen J.O. Increased risk of infection with hepatitis A and B viruses in men with a history of syphilis relation to sexual contacts . J Infect Dis. 145:1982;23-26.
14. Hepatitis A among drug abusers. MMWR. 37:1988;297-305.
15. Suharto TA, Jacobson I. Prevalence of hepatitis A antibodies in HCV-infected persons in New York City. Am J Gastroenterol. 1998;93:286. Abstract.
16. Bryan J.P., Nelson M. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccine. Arch Intern Med. 154:1994;663-668.
17. Bader T.F. Hepatitis A vaccine. Am J Gastroenterol. 91:1996;217-222.
18. Smith S., Weber S., Wiblin T., Nettleman M. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect Control Hosp Epidemiol. 18:1997;688-691.
19. Buma A.H., Beutels P., van Damme P., et al. An economic evaluation of hepatitis A vaccination in Dutch military personnel. Milit Med. 163:1998;564-567.
20. Polesky H., Hanson M. Comparison of viral hepatitis marker test methods based on AABP-CAP survey data. Am J Clin Pathol. 76:1981;84-91.
21. Clemens R., Safary A., Hepburn A., et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis. 171:1995;S44-S49.
22. Petitti DB, ed. Sensitivity analysis. In: Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. 2nd ed. New York: Oxford University Press; 1994:229-243.